Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
AFT Leaves X Over AI-Generated Images of Minors 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
NEWTON, Mass., March 29, 2017 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference in New York on Wednesday, April 5, 2017 at 3:00 p.m. ET.
A live webcast of the event can be accessed under "Events & Presentations" in the Investors section of the Company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,900 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
Contacts: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
